Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 8/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL333952 | 0.81 | ALDH1A1 (0.44) | SMN1; SMN2CYP1A2CYP2A6KDM4ETP53 | |
| SCHEMBL4273522 | 0.80 | SMN1; SMN2 (0.45) | SMN1; SMN2SYKARKIF11CYP1A2 | |
| SCHEMBL12859720 | 0.79 | SMN1; SMN2 (0.41) | SMN1; SMN2SYKARKIF11CYP1A2 | |
| SCHEMBL84053 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2SYKARKIF11CYP1A2 | |
| SCHEMBL10030392 | 0.78 | GLA (0.54) | SMN1; SMN2SYKARKIF11CYP1A2 | |
| SCHEMBL168982 | 0.76 | MPL (0.44) | SMN1; SMN2SYKARCYP11B1CYP11B2 | |
| SCHEMBL81146 | 0.75 | SMN1; SMN2 (0.37) | SMN1; SMN2SYKARCYP1A2FFAR4 | |
| SCHEMBL169128 | 0.74 | MAPT (0.53) | SMN1; SMN2SYKARKIF11MAPT | |
| SCHEMBL14748151 | 0.74 | SMN1; SMN2 (0.46) | SMN1; SMN2SYKARKIF11CYP1A2 | |
| SCHEMBL6371416 | 0.74 | SMN1; SMN2 (0.43) | SMN1; SMN2SYKARKIF11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4174069-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2023-05-03 | — | — | EP | disclosed |
| US-11535603-B1 | Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same | DEUTERX, LLC (US) | 2022-12-27 | — | — | US | disclosed |
| US-8129002-B2 | Compounds for use in liquid crystal media | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535603-B1 | Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same | EGLN3, HPGDS, EGLN2 | SMN1; SMN2 2161/4885SYK 1426/4885AR 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.